scholarly journals Effect of antiepileptic drugs on plasma fibrinogen level

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
R. El-Ashry ◽  
M.M. El-Ayuoty ◽  
H.A. Azzam ◽  
M.A. El-Naggar
Keyword(s):  
Antiepileptic Drugs ◽  
Cognitive Deficits ◽  
Neurological Disorders ◽  
Epileptic Patient ◽  
Fibrinogen Level ◽  
Developed Countries ◽  
Plasma Fibrinogen ◽  
Newly Diagnosed ◽  
Plasma Fibrinogen Level ◽  
Active Epilepsy

Background: Childhood  epilepsy  is  one  of  the  most  common  neurological  disorders  in pediatrics . The  prevalence  of  active  epilepsy is 5–8 per 1000 population  in developed countries  and  10 per 1000  population in  developing nations . There is a significant relationship between epilepsy and cognitive deficits. Aim of study: prospective study to evaluate the effect of the most commonly used anti-epileptics drugs on plasma fibrinogen level. Patient and methods 100 newly diagnosed patients (2months to 15 years old) selected from Outpatient Clinic of Neurology attending Mansoura University Children’s Hospital for plasma fibrinogen level evaluation by taking basal sample and second sample after six months after the basal one. Results: This study showed that, significant positive correlation between plasma fibrinogen level and the use of antiepileptic drugs. Conclusion: epileptic patient should be closely monitored during Antiepileptic drugs treatment and prior to surgical procedures as they can affect plasma fibrinogen level and coagulation profile.

Platelet Adhesiveness and Fibrinolysis after Recent Cerebro-Vascular Accidents and their Relationship with Subsequent Deep Venous Thrombosis of the Legs

1976 ◽  
Vol 36 (01) ◽  
pp. 127-132 ◽  
Author(s):  
C. P Warlow ◽  
J. A. N Rennie ◽  
D Ogston ◽  
A. S Douglas
Keyword(s):  
Platelet Count ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Plasminogen Activator ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Platelet Adhesiveness ◽  
Plasma Fibrinogen Level ◽  
Vascular Accidents ◽  
Subsequent Rise

SummaryIn fifteen patients with a cerebro-vascular accident resulting in an acute hemiplegia there was a subsequent rise in the platelet count and plasma fibrinogen level. There were no significant alterations in platelet adhesiveness, plasminogen activator, plasminogen, FR-antigen and haematocrit. Patients diagnosed as developing deep venous thrombosis with the 125I-fibrinogen technique had a significantly lower platelet adhesiveness and plasminogen level than those who were not.

Variation in the Promoter Region of the β Fibrinogen Gene Is Associated with Plasma Fibrinogen Levels in Smokers and Non-Smokers

1991 ◽  
Vol 65 (05) ◽  
pp. 487-490 ◽  
Author(s):  
A E Thomas ◽  
F R Green ◽  
C H Kelleher ◽  
H C Wilkes ◽  
P J Brennan ◽  
...  
Keyword(s):  
Heart Disease ◽  
Promoter Region ◽  
Fragment Length Polymorphism ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Plasma Fibrinogen Level ◽  
Healthy Men ◽  
History Of ◽  
General Practices ◽  
Restriction Fragment Length

SummaryWe investigated the association between fibrinogen levels and a HaeIII restriction fragment length polymorphism located at −453 bp from the start of transcription of the β fibrinogen gene. 292 healthy men aged 45 to 69 years, recruited from general practices throughout Britain, were studied. None had a history of ischaemic heart disease. 41.1% (120) were smokers and fibrinogen levels were higher in this group. The frequency of the noncutting allele (designated H2) was 0.19 and was the same in smokers and non-smokers. The H2 allele was associated with elevated levels of fibrinogen in both smokers and non-smokers and the effect of genotype was similar in both groups. After smoking, HaeIII genotype was the strongest predictor of fibrinogen levels and explained 3.1% of the variance in fibrinogen levels. These results confirm earlier studies that variation at the fibrinogen locus contributes to the between-individual differences in plasma fibrinogen level.

A Six Year Prospective Study of Fibrinogen and Other Risk Factors Associated with Mortality in Stable Claudicants

1992 ◽  
Vol 68 (03) ◽  
pp. 261-263 ◽  
Author(s):  
A K Banerjee ◽  
J Pearson ◽  
E L Gilliland ◽  
D Goss ◽  
J D Lewis ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intermittent Claudication ◽  
Fibrinogen Level ◽  
Past History ◽  
Fold Increase ◽  
Arterial Disease ◽  
Plasma Fibrinogen ◽  
Plasma Fibrinogen Level ◽  
Factors Associated ◽  
Probability Of Death

SummaryA total of 333 patients with stable intermittent claudication at recruitment were followed up for 6 years to determine risk factors associated with subsequent mortality. Cardiovascular diseases were the underlying cause of death in 78% of the 114 patients who died. The strongest independent predictor of death during the follow-up period was the plasma fibrinogen level, an increase of 1 g/l being associated with a nearly two-fold increase in the probability of death within the next 6 years. Age, low ankle/brachial pressure index and a past history of myocardial infarction also increased the probability of death during the study period. The plasma fibrinogen level is a valuable index of those patients with stable intermittent claudication at high risk of early mortality. The results also provide further evidence for the involvement of fibrinogen in the pathogenesis of arterial disease.

scholarly journals An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients

The Breast ◽  
2015 ◽  
Vol 24 (5) ◽  
pp. 667-672 ◽  
Author(s):  
Sabine Krenn-Pilko ◽  
Uwe Langsenlehner ◽  
Tatjana Stojakovic ◽  
Martin Pichler ◽  
Armin Gerger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Plasma Fibrinogen Level ◽  
Breast Cancer Patients ◽  
Disease Specific

scholarly journals Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Yuriy K. Bashmakov ◽  
Samir H. Assaad-Khalil ◽  
Myriam Abou Seif ◽  
Ruzan Udumyan ◽  
Magdy Megallaa ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fibrinogen Level ◽  
Foot Ulcer ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Plasma Fibrinogen Level ◽  
Type 2 Diabetic Patients ◽  
Ulcer Size ◽  
Type 2 Diabetic

Objective. The effect of a proprietary formulation of trans-resveratrol (t-RSV) on manifestations of diabetic foot syndrome (DFS) was studied in type 2 diabetic patients with newly diagnosed diabetic foot ulcers. Method. Placebo-controlled, examiner-blinded, parallel-group randomized controlled pilot clinical trial (ACTRN Clinical Trial Registry number 12610000629033) involving 24 patients with DFS (15 males and 9 females, average age of 56.4±9.1 years) divided into the placebo and RSV-treatment groups was performed. 50 mg of t-RSV or placebo capsules was given to each patient twice a day over a 60-day time period. Results. Reduction in the parameters reflecting diabetic ulcer size was more profound in the RSV group as compared to placebo. RSV-treated patients also had a marginally improved performance in the foot pressure test. A statistically significant decline in the plasma fibrinogen level, but not CRP, was also found in the RSV-treated patients. Some improvement in the plasma lipid profile and fasting glucose levels were not related to RSV-treatment, since they have been seen on both the RSV and placebo groups, revealing the effectiveness of medical supervision and education in the newly diagnosed patients with DFS. Conclusion. t-RSV supplementation promotes reduction of the foot ulcer size and reduces plasma fibrinogen level in type 2 diabetic patients.

Sign in / Sign up

Export Citation Format

Share Document